Cutter & CO Brokerage Inc. Takes Position in Eli Lilly and Company (NYSE:LLY)

Cutter & CO Brokerage Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 840 shares of the company’s stock, valued at approximately $232,000.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Two Sigma Advisers LP boosted its holdings in shares of Eli Lilly and by 6,719.9% during the 3rd quarter. Two Sigma Advisers LP now owns 2,025,500 shares of the company’s stock worth $467,992,000 after buying an additional 1,995,800 shares during the period. Capital World Investors raised its stake in shares of Eli Lilly and by 9.8% in the 3rd quarter. Capital World Investors now owns 16,790,382 shares of the company’s stock valued at $3,879,410,000 after buying an additional 1,502,363 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Eli Lilly and by 1,509.0% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,054,479 shares of the company’s stock worth $243,637,000 after purchasing an additional 988,944 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Eli Lilly and by 1,123.5% during the 3rd quarter. Renaissance Technologies LLC now owns 1,053,447 shares of the company’s stock worth $243,399,000 after purchasing an additional 967,347 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Eli Lilly and by 7.2% during the 4th quarter. Fisher Asset Management LLC now owns 6,982,910 shares of the company’s stock worth $1,928,820,000 after purchasing an additional 470,522 shares in the last quarter. Institutional investors and hedge funds own 82.75% of the company’s stock.

Several equities research analysts have weighed in on the stock. Mizuho raised their price objective on shares of Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Bank of America lifted their price objective on shares of Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Morgan Stanley lifted their price objective on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. DZ Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 target price on the stock in a report on Friday, January 21st. Finally, StockNews.com downgraded shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and has a consensus rating of “Buy” and a consensus target price of $302.56.

In related news, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was sold at an average price of $243.84, for a total value of $404,774.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Ilya Yuffa sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $237.45, for a total value of $237,450.00. The disclosure for this sale can be found here. Insiders sold 1,088,551 shares of company stock valued at $307,943,730 in the last ninety days. 0.12% of the stock is currently owned by insiders.

Eli Lilly and stock opened at $291.63 on Friday. The business has a 50 day moving average of $289.22 and a 200-day moving average of $266.38. Eli Lilly and Company has a 1 year low of $193.11 and a 1 year high of $314.00. The company has a debt-to-equity ratio of 1.60, a current ratio of 1.27 and a quick ratio of 0.98. The company has a market capitalization of $277.10 billion, a P/E ratio of 43.20, a P/E/G ratio of 2.27 and a beta of 0.40.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The company had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter in the prior year, the firm posted $1.87 earnings per share. The firm’s revenue was up 14.8% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 8.25 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Monday, May 16th will be paid a $0.98 dividend. This represents a $3.92 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.